Egyptian Prime Minister Mostafa Madbouly has awarded Gennvax Egypt the golden license to develop and manage the largest scientific and regional R&D center and a facility to locally manufacture and export all types of vaccines to the African continent.
This license authorizes the firm to build and run the world’s first and biggest pharmaceutical, vaccine, and medical serum manufacturing facility. The plant will feature a full manufacturing cycle and comprehensive technology transfer, guaranteeing that it is built to satisfy the highest worldwide standards.
Importantly, the International Health Organization approvals for the export of WHO PQ vaccines will be obtained as part of the establishment process, where a significant portion of the foreign direct investment will be allocated to maintain the WHO PQ accreditations and standards; it is emphasized that the PQ should be an integral part of the facility establishment step by step. The project will cost $150 million and will cover an area of roughly 49,000 square meters.
Nibal Dahaba, shareholder, board member, and General Manager of Gennecs Company and Gennvax Holding, expressed her pride in the successful acquisition of the golden license for Gennvax Egypt to establish and operate a vaccine manufacturing plant. She stated that this significant milestone strongly aligns with the company’s strategy, which recognizes the vaccine industry as a vital sector with substantial contributions to the national economy. The establishment of the plant will enhance the company’s role in producing and innovating vaccines necessary for treating various diseases. Dahaba also mentioned that the project is anticipated to create between 500 and 700 job opportunities.
Adam Al-Daba, CEO of Gennecs Company and Gennvax Holding, stated that the upcoming factory will become the largest of its kind in manufacturing all human vaccines, encompassing a complete production cycle that includes 19 different types of vaccines with full technology transfer. Notably, the factory will be equipped with advanced technology that positions it as a major hub for exporting medical vaccines to countries across Africa and globally. It has been built to meet the highest international standards, and to be eligible for “WHO” approvals, which will enable exports to all countries worldwide. Mr. Al- Daba further highlighted that a substantial portion of the project’s investments, approximately $60 million, has been allocated towards obtaining the necessary WHO PQ approvals for vaccine manufacturing, accreditation and export.
Dahaba provided insightful details on the impressive production capabilities of the new vaccine factory. According to her, the factory’s production capacity is set to reach an estimated 115 million doses per year on a single shift basis. However, this number can be easily doubled to 250 million doses, showcasing the factory’s potential for significant expansion. Moreover, the new facility will house a research & development center dedicated to the full R&D technologies and advanced biological research. Additionally, it will feature all the cold chain high tech supply chain that would cater the whole continent
One of the features of the new factory is the strain bank customized to be specific to Africa, which will enable the facility to manufacture vaccines related to any African or regional pandemic promptly.
This golden license is a major tool in attracting investors to work within Egypt’s borders, while also attracting foreign investments that can enhance the Egyptian economy and lead to an increase in the country’s domestic product, contributing to the desired economic development. Moreover, Gennvax project will be a new source of foreign currency and an export door, which will help to boost the Egyptian economy and promote the country’s international trade. This is expected to have a positive impact on the country’s economic growth and development, creating new opportunities for job creation and improving living standards.
